BPH Global Enters Stage 2 of Indonesian Fucoidan Research Partnership

BPH Global enters Stage 2 of Indonesian research partnership

BPH Global has progressed its collaboration with Indonesia’s National Research and Innovation Agency (BRIN) to Stage 2, executing binding agreements to develop fucoidan extraction technology and a powdered supplement prototype for food and beverage applications. The move transitions the partnership from framework collaboration (Stage 1) to active project execution, with prototype delivery anticipated within approximately 3 months from commencement.

The development follows a binding Memorandum of Understanding (MoU) announced on 6 February 2026. PT BPH Global Indonesia, the company’s operating subsidiary, has formalised Stage 2 through a Cooperation Agreement and detailed Terms of Reference. Work is expected to commence within the coming week.

This progression from MoU to binding project agreements demonstrates tangible execution on the partnership, moving (ASX: BP8) from strategic intent to active R&D work with Indonesia’s peak research body.

What is fucoidan and why does it matter?

Fucoidan is a bioactive compound derived from brown seaweed, widely utilised globally in functional foods, nutraceuticals and cosmetic applications. For BPH Global, which already operates as a commercial seaweed supplier and exporter, fucoidan represents a value-add downstream product opportunity that could transform raw seaweed commodity sales into higher-margin bioactive ingredient supply.

BRIN holds existing registered background intellectual property in Indonesia for fucoidan extraction technology, which underpins this collaboration. The project aims to establish domestic Indonesian fucoidan production capability, reducing reliance on imports whilst supporting downstream industry applications.

Fucoidan extraction positions BPH Global to capture value further up the supply chain. Rather than exporting raw seaweed, the company could potentially supply standardised fucoidan extract for functional food and nutraceutical manufacturers across Southeast Asian markets.

Stage 2 project scope and deliverables

The collaborative R&D project encompasses several technical workstreams:

• Joint research and technical development
• Raw material characterisation
• Scale-up of extraction processes to 10kg input level
• Quality standardisation
• Development of fucoidan-based powdered supplement prototype

Expected outputs from Stage 2 include:

• Fucoidan extract prototype and specifications
• Draft intellectual property outcome
• Development of fucoidan as a nutraceutical raw material

The 10kg scale-up target indicates this is not a laboratory curiosity but a prototype designed with commercial scalability in mind. The draft IP outcome suggests potential for formalised rights to emerge from this work, which could inform licensing discussions in Stage 3.

Financial contributions and project value

The Stage 2 project will be funded through a combination of direct expenditure by BPH Global and in-kind contributions from BRIN. Each party will bear its respective costs in accordance with the Cooperation Agreement.

BPH Global’s contribution includes:

• Raw seaweed materials
• Labour and technical support
• Chemicals and processing inputs
• Supporting materials
• Rental of production equipment (extraction and drying systems)

BRIN’s contribution includes:

• Laboratory testing and analytical services (FTIR, GPC, UV-Vis and related analysis)

A ~$14,600 cash contribution for access to Indonesia’s national research infrastructure and registered IP represents a capital-efficient pathway to R&D capability. The modest capital outlay relative to the strategic opportunity provides leveraged exposure to fucoidan commercialisation potential.

Pathway to commercialisation

The partnership follows a structured progression through defined stages. Stage 1 established the framework collaboration through the MoU. Stage 2 delivers proof-of-concept through prototype development. Successful prototype completion is expected to inform progression to Stage 3, focused on commercialisation.

Upon successful completion of the prototype phase, the parties intend to:

1. Assess technical and commercial viability
2. Progress discussions regarding licensing of BRIN technology
3. Consider advancement to Stage 3, expected to be governed by separate commercial agreements

This staged approach provides visibility on milestones. Licensing discussions on BRIN’s registered IP could establish BPH Global’s position in Indonesian fucoidan production at an early stage of market development, potentially ahead of broader industry adoption.

BRIN’s role in Indonesia’s “research down streaming” (hilirisasi) strategy is central to this partnership structure. The agency seeks to translate publicly funded research into applied technologies and commercially viable outcomes through structured collaboration with industry across priority sectors including marine bioindustry, advanced materials and agriculture.

About BRIN

Badan Riset dan Inovasi Nasional (BRIN) is Indonesia’s National Research and Innovation Agency, a cabinet-level government institution operating under the President of the Republic of Indonesia. BRIN is responsible for coordinating, conducting and promoting research, development, assessment and application of science and technology across Indonesia.

The agency operates across priority sectors relevant to BPH Global, including marine bioindustry, advanced materials and agriculture. Partnership with a cabinet-level government agency provides credibility and potential access to further research infrastructure and policy support as the fucoidan development programme advances through subsequent stages.

Get ASX Biotech News Before the Market Reacts

Join 20,000+ investors receiving FREE breaking news and expert analysis on ASX biotechnology stocks, delivered to your inbox within minutes of release. Click the “Free Alerts” button at Big News Blast to receive market-moving announcements the moment they drop.